Cholangiocarcinoma News

Exciting New Abstracts from the ASCO GI Cancers Symposium

March 2023, Vol 4, No 1
Milind M. Javle, MD
Hubert L. and Olive Stringer Professor
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas
M.D. Anderson Cancer Center
Houston, TX
NCI Task Force: Hepatobiliary Cancers

Dear Readers,

In this issue of CCA News, we are highlighting important abstracts presented at the ASCO Gastrointestinal Cancers Symposium (ASCO GI23; January 19-21, 2023; San Francisco, CA). Each year, the number of biliary tract cancer (BTC) abstracts presented at this annual meeting has increased, and 2023 was no exception. Dr Rachna Shroff presented on the randomized, phase 3 trial of gemcitabine/cisplatin (GemCis) with or without nab-paclitaxel. Although this trial did not meet its prespecified end point of improved overall survival when compared with standard-of-care chemotherapy, there were important observations that are instructive in the field. First, such a large phase 3 trial is possible in BTC in the United States, and subtypes of these cancers can be targeted by incremental chemotherapies.

IMbrave 151 was another important study, and the findings were presented of which were presented by Dr Anthony El-Khoueiry. In this randomized, phase 2 study, researchers investigated the combination of atezolizumab with or without bevacizumab plus chemotherapy in patients with advanced BTC. Researchers demonstrated the feasibility of such a combination, although the clinical benefit of this strategy remains to be determined.

Currently, GemCis and durvalumab remain the standard of care in the first line. At ASCO GI23, we learned about the value of the addition of durvalumab in specific molecular subtypes, including KRAS mutation, which is associated with an aggressive clinical prognosis. The molecular sequencing data from TOPAZ-1 have provided key insights into the genetic profile of BTC in the first-line setting.

The ASCO GI23 presentations on novel targeted therapies included promising data on the FGFR inhibitor gunagratinib, CTX-009 (a bispecific antibody targeting delta-like ligand 4/Notch-1 and VEGF), and BI 907828, which targets MDM2-p53. It is hoped that these studies will bring novel agents for patients with specific molecular and clinical subtypes of BTC.

Exciting new updates are expected from the KEYNOTE-966 trial with pembrolizumab later this year, and a recent announcement indicated that this study of GemCis with or without pembrolizumab has met its primary end point of overall survival improvement. This is a landmark achievement, and we eagerly await further updates!


Milind M. Javle, MD

Related Items

Highlights from the Fourth Annual CCA Summit
By Milind M. Javle, MD
December 2022, Vol 3, No 4
We have recently concluded the 4th Annual CCA Summit, which was held on October 13-15, 2022, in Denver, Colorado.
New Standard of Care Emerging for Treatment of BTCs
By Milind M. Javle, MD
September 2022, Vol 3, No 3
On September 2, 2022, the US Food and Drug Administration approved durvalumab in combination with gemcitabine/cisplatin for advanced biliary tract cancers (BTCs) on the basis of the TOPAZ-1 study.
Rapid Trajectory of Clinical Research in Biliary Tract Cancers
By Milind M. Javle, MD
March 2022, Vol 3, No 1
The 2022 ASCO GI Cancers Symposium clearly highlighted the rapid trajectory of clinical research in biliary tract cancers. One of the most eagerly anticipated studies, TOPAZ-1, was presented by Do-Youn Oh, MD, PhD, from Seoul National University Hospital in South Korea. This phase 3 clinical trial enrolled 685 patients and investigated the addition of the PD-L1–directed agent durvalu­mab to gemcitabine and cisplatin chemotherapy backbone versus these chemotherapies alone. The results demonstrated a statistically significant improvement in overall survival (OS), overall response rate (ORR), and progression-free survival (PFS), without dose-limiting toxicities.
Hot Topics at ASCO-GI 2022
By Milind M. Javle, MD
Dr Milind Javle provides his perspectives on key presentations on cholangiocarcinoma and biliary tract cancer at the 2022 ASCO Gastrointestinal Cancers Symposium.
Cholangiocarcinoma Research Continues to Thrive
By Milind M. Javle, MD
December 2021, Vol 2, No 4
The Third CCA Summit was held on October 21-22, 2021 in New Orleans. For the majority of the cholangiocarcinoma (CCA) community, this was their first “live” meeting since the pandemic.
Mechanisms of Resistance to FGFR Inhibitors
By Jesús Bañales, PhD; Antoine Hollebecque, MD; Milind M. Javle, MD; Angela Lamarca, MD, PhD, MSc
Drs Javle, Bañales, and Hollebecque discuss the innate and acquired resistance pathways to FGFR inhibitors in cholangiocarcinoma and how these pathways can have important effects on clinical outcomes. They also look ahead to ongoing clinical trials evaluating next-generation FGFR inhibitors that may be able to overcome resistance mechanisms and improve progression-free and overall survival in cholangiocarcinoma.
Molecular Profiling Should Now Be Routine Practice in Patients with CCA
By Milind M. Javle, MD
September/October 2021, Vol 2, No 3
This issue of CCA News features yet another exciting FDA approval for cholangiocarcinoma (CCA), ivosidenib, which was recently approved for CCA with IDH1 mutation. This is the third drug approved for CCA in the past 2 years, highlighting the critical role of molecular profiling in this cancer. Up to 20% of patients with intrahepatic CCA have IDH1 mutation, and the ClarIDHy phase 3 study demonstrated improvement in progression-free survival with ivosidenib versus placebo for chemorefractory disease. The FDA also approved the Oncomine Dx Target Test for IDH1 mutations.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: